- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04260802
A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers
November 27, 2023 updated by: Ocellaris Pharma, Inc.
A Phase 1b/2a Two-Part, Open-Label, Multicenter Study to Evaluate the Safety and Pharmacokinetics of OC-001 as Monotherapy and in Combination With an Anti-PD-1/Anti-PD-L1 Antibody in Patients With Selected Locally Advanced or Metastatic Cancers
This study will investigate OC-001 as monotherapy, and in combination with an anti-Programmed Cell Death Protein-1 (PD-1) or anti-Programmed Cell Death Ligand-1 (PD-L1) Antibody inhibitor, in various cancer types
Study Overview
Status
Recruiting
Conditions
- Sarcoma
- Neoplasms
- Renal Cell Carcinoma
- Cervical Cancer
- Cancer
- Hepatocellular Carcinoma
- Gastric Cancer
- Ovarian Cancer
- Non Small Cell Lung Cancer
- Metastatic Cancer
- Squamous Cell Carcinoma of Head and Neck
- Bladder Cancer
- Triple Negative Breast Cancer
- Urothelial Carcinoma
- Merkel Cell Carcinoma
- Squamous Cell Carcinoma
- Locally Advanced Malignant Neoplasm
- Locally Advanced Solid Tumor
- Urothelial Neoplasm
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
80
Phase
- Phase 2
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Study Director: Ocellaris Pharma, Inc
- Phone Number: 3176517036
- Email: choruspharma@lists.lilly.com
Study Locations
-
-
Alberta
-
Edmonton, Alberta, Canada, T6G 1Z2
- Recruiting
- Cross Cancer Institute
-
Contact:
- Quincy Chu
- Phone Number: 780-432-8248
-
Principal Investigator:
- Quincy Chu
-
-
Ontario
-
Ottawa, Ontario, Canada
- Recruiting
- Ottawa Hospital Cancer Centre (OHRI)
-
Contact:
- Derek Jonker
- Phone Number: 70185 613-737-7700
- Email: djonker@toh.ca
-
Principal Investigator:
- Derek Jonker
-
Toronto, Ontario, Canada, M5G 2C1
- Recruiting
- Princess Margaret Hospital
-
Contact:
- Amit Oza
- Phone Number: 416-946-2818
-
Principal Investigator:
- Amit Oza
-
-
Quebec
-
Montreal, Quebec, Canada, H3T 1E2
- Recruiting
- Jewish General Hospital - Clinical Research Unit
-
Principal Investigator:
- Wilson Miller
-
Contact:
- Ivgenya Kosenko
- Phone Number: 25981 514-340-8222
- Email: ivgenya.kosenko.ccomtl@ssss.gouv.qc.ca
-
Montréal, Quebec, Canada, H2X 0A9
- Recruiting
- Centre hospitalier de l'Université de Montréal (CHUM)
-
Contact:
- Marie-Eve Rego
- Phone Number: 30758 514-890-8000
- Email: marie-eve.rego.chum@ssss.gouv.qc.ca
-
Principal Investigator:
- Diane Provencher
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
Have histological or cytological evidence of a diagnosis of selected cancer types that is locally advanced and/or metastatic
- Have the presence of evaluable disease for the Phase 1b part of the study
- Have the presence of evaluable and measurable disease for the Phase 2a part of the study
- The patient must be, in the judgment of the investigator, an appropriate candidate for experimental therapy after available standard therapies have failed to provide clinical benefit for their disease or patients who have refused standard treatments.
Cancer treatment and type criteria:
- Have received at least 1 but no more than 4 prior systemic therapies for locally advanced or metastatic disease (e.g., hormonal, cytotoxic, etc.) for the following cancer types, for Phase 1b:
- Triple Negative Breast Cancer (TNBC): Must have recurrent/refractory TNBC, defined as any breast cancer that expresses less than (˂)1% estrogen receptor (ER), ˂ 1% progesterone receptor (PR), and is Human Epidermal Growth Factor Receptor 2 (Her2) negative. Must have failed at least one chemotherapy regimen.
- Gastric Cancer: Must have failed a platinum-containing chemotherapy regime.
- Cervical Cancer: Must have failed at least one chemotherapy regimen.
- Ovarian Cancer: Must have failed a platinum-containing chemotherapy regimen but not be platinum refractory.
- Hepatocellular Cell Carcinoma (HCC): May have failed unlimited liver local therapies.
- Sarcoma: Must have failed at least one prior chemotherapy regimen.
- Squamous Cell Carcinoma of Head and Neck (SCCHN): Must have failed a platinum-containing chemotherapy regiment. Must have failed a previous immune checkpoint inhibitor.
- Bladder Cancer: Must have failed a platinum-containing chemotherapy regiment. Must have failed a previous immune checkpoint inhibitor.
- Non Small Cell Lung Cancer (NSCLC): Must have failed a platinum-containing chemotherapy regimen or Immuno Oncology (IO) agent in the first line. Must have failed a previous immune checkpoint inhibitor. Must not have any history of tumors that test positive for epidermal growth factor receptor (EGFR), Receptor Tyrosine Kinase (ROS1) , Anaplastic Lymphoma Kinase (ALK) mutations or ALK fusions or any other mutations for which tyrosine kinase inhibitors are available.
- Renal Cell Carcinoma (RCC): Must have failed at least one prior systemic therapy. Must have failed a previous IO agent.
- Urothelial Cancer: Must have failed at least one prior systemic therapy. Must have failed a previous IO agent.
- Merkel Cell: Must have failed at least 1 prior systemic therapy for advanced disease and may have failed a previous IO agent.
- Squamous Cell Carcinoma of the Skin: Must have failed at least 1 prior systemic therapy for advanced disease and may have failed a previous IO agent.
- For Phase 2a: Must have histological or cytological confirmation of a solid tumor that is locally advanced or metastatic. At least one cancer type will be selected amongst the ones evaluated in the Phase 1b part of the study.
- Have adequate organ function
- Have a performance status (PS) of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG) scale
- Have discontinued cytotoxic therapy, biologic therapy, immunotherapy, radiotherapy, and cancer-related hormonal therapy at least 21 days prior to study enrollment
- Are recovered or recovering from the acute adverse effects of any chemotherapy, biologic, therapy, immunotherapy, cancer-related hormonal therapy, or radiotherapy
- Patients who have had major surgery must be fully recovered and greater than (≥)4 weeks post-operative
- Men with partners of child-bearing potential or women with child-bearing potential must agree to use a medically approved contraceptive method during and for at least 12 weeks following the last dose of study drug (e.g., intrauterine device (IUD), birth control pills, or barrier method)
- Women of child-bearing potential must have a negative serum pregnancy test documented
- Have an estimated life expectancy of at least 3 months
Exclusion Criteria:
- Have symptomatic central nervous system (CNS) metastasis. Patients with treated CNS metastases are eligible for this study if they are asymptomatic and off of corticosteroids for a minimum of 7 days. Patients with primary brain tumors are not eligible
- Have a history of major organ transplant (e.g., heart, lungs, liver, and kidney) or an autologous or allogeneic hematopoietic stem cell transplant
- Females who are pregnant or nursing
- Have known, symptomatic acquired immuno deficiency syndrome (AIDS) or active hepatitis A, B or C
- Previous treatment-related, severe (≥Grade 3) Adverse Event (AE) or any neurologic or ocular AE while receiving an IO agent
- Active or prior documented autoimmune disease within the past 2 years Patients with vitiligo, Grave's disease or psoriasis not requiring systemic treatment within the past 2 years are eligible
- Active or prior documented inflammatory bowel disease
- History of tuberculosis, interstitial lung disease (ILD), drug-induced ILD, radiation pneumonitis which required corticosteroid therapy
- Receipt of live attenuated vaccination within 28 days prior
- Current or prior use of immunosuppressive medication within 28 days prior
- Are currently enrolled in another clinical study of an investigational medicinal product
- Have a second primary malignancy that may affect the interpretation of results
- Are unwilling or unable to participate in, or do not have tissue adequate for a tumor biopsy
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Drug: Dose Escalation
Escalating doses of OC-001 administered intravenously (IV)
|
Monotherapy in Phase 1b
|
Experimental: Drug: Combination: Tumor Type 1
Doses of OC-001 administered by IV in combination anti-PD-1 or anti-PD-L1 Antibody (Ab)
|
Anti-PD-1/anti-PD-L1 Ab administered per approved prescribing schedule, in Phase 2a
|
Experimental: Drug: Combination: Tumor Type 2
Doses of OC-001 administered by IV in combination anti-PD-1 or anti-PD-L1 Antibody (Ab)
|
Anti-PD-1/anti-PD-L1 Ab administered per approved prescribing schedule, in Phase 2a
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of participants with a Dose Limiting Toxicity (DLT) in Phase 1b
Time Frame: Baseline through Cycle 1 (Day 28)
|
A Dose-Limiting Toxicity (DLT) is defined as an Adverse Event (AE) that is likely related to the study medication or combination, and fulfills any one of the criteria identified in the Common Terminology Criteria for Adverse Events (CTCAE, Version 5)
|
Baseline through Cycle 1 (Day 28)
|
Number of participants with any Serious Adverse Event or Treatment-Emergent Adverse Event in Phase 2a
Time Frame: Baseline up to two years
|
Number of participants with any Serious Adverse Event or Treatment-Emergent Adverse Event in Phase 2a
|
Baseline up to two years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Area Under the OC-001 Plasma Concentration Time Curve (AUC) in Phase 1b
Time Frame: Baseline through 12 weeks
|
After single and multiple dose administration
|
Baseline through 12 weeks
|
Maximum Observed OC-001 Concentration (Cmax) in Phase 1b
Time Frame: Baseline through 12 weeks
|
After single and multiple dose administration
|
Baseline through 12 weeks
|
Time to reach OC-001 Cmax (Tmax) in Phase 1b
Time Frame: Baseline through 12 weeks
|
Time of maximum concentration observed
|
Baseline through 12 weeks
|
Minimum Observed OC-001 Concentration (Cmin) in Phase 1b
Time Frame: Baseline through 12 weeks
|
After single and multiple dose administration
|
Baseline through 12 weeks
|
Overall Response Rate (ORR) in Phase 2a
Time Frame: Baseline up to two years
|
In combination with an anti-PD-1 or anti-PD-L1 antibody
|
Baseline up to two years
|
Progression Free Survival (PFS) in Phase 2a
Time Frame: Baseline up to two years
|
In combination with an anti-PD-1 or anti-PD-L1 antibody
|
Baseline up to two years
|
Duration of Response (DOR) in Phase 2a
Time Frame: Baseline up to two years
|
In combination with an anti-PD-1 or anti-PD-L1 antibody
|
Baseline up to two years
|
Time to Response (TTR) in Phase 2a
Time Frame: Baseline up to two years
|
In combination with an anti-PD-1 or anti-PD-L1 antibody
|
Baseline up to two years
|
Disease Control Rate (DCR) in Phase 2a
Time Frame: Baseline up to two years
|
In combination with an anti-PD-1 or anti-PD-L1 antibody
|
Baseline up to two years
|
Overall Survival (OS) in Phase 2a
Time Frame: Baseline up to two years
|
In combination with an anti-PD-1 or anti-PD-L1 antibody
|
Baseline up to two years
|
One-Year Survival Rate in Phase 2a
Time Frame: Baseline up to two years
|
In combination with an anti-PD-1 or anti-PD-L1 antibody
|
Baseline up to two years
|
Maximum Observed OC-001 Concentration (Cmax) in Phase 2a
Time Frame: Baseline through 12 weeks
|
In combination with an anti-PD-1 or anti-PD-L1 antibody
|
Baseline through 12 weeks
|
Minimum Observed OC-001 Concentration (Cmin) in Phase 2a
Time Frame: Baseline through 12 weeks
|
In combination with an anti-PD-1 or anti-PD-L1 antibody
|
Baseline through 12 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Ocellaris Pharma, Inc, Ocellaris Pharma, Inc.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
October 6, 2020
Primary Completion (Estimated)
March 31, 2026
Study Completion (Estimated)
September 30, 2026
Study Registration Dates
First Submitted
February 5, 2020
First Submitted That Met QC Criteria
February 5, 2020
First Posted (Actual)
February 7, 2020
Study Record Updates
Last Update Posted (Actual)
November 28, 2023
Last Update Submitted That Met QC Criteria
November 27, 2023
Last Verified
November 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Skin Diseases
- Virus Diseases
- Infections
- Neoplasms by Histologic Type
- Neoplasms by Site
- Adenocarcinoma
- Neoplasms, Glandular and Epithelial
- Breast Diseases
- Head and Neck Neoplasms
- Neuroectodermal Tumors
- Neoplasms, Germ Cell and Embryonal
- Neoplasms, Nerve Tissue
- DNA Virus Infections
- Neoplastic Processes
- Tumor Virus Infections
- Neuroendocrine Tumors
- Neoplasms, Squamous Cell
- Polyomavirus Infections
- Carcinoma, Neuroendocrine
- Breast Neoplasms
- Neoplasms
- Carcinoma
- Neoplasm Metastasis
- Carcinoma, Squamous Cell
- Squamous Cell Carcinoma of Head and Neck
- Triple Negative Breast Neoplasms
- Carcinoma, Merkel Cell
- Neoplasms, Second Primary
Other Study ID Numbers
- OCEL-01
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Sarcoma
-
Albert Einstein College of MedicineNational Cancer Institute (NCI)TerminatedUterine Corpus Leiomyosarcoma | Stage IIA Uterine Sarcoma | Stage IIB Uterine Sarcoma | Stage IIIA Uterine Sarcoma | Stage IIIB Uterine Sarcoma | Stage IIIC Uterine Sarcoma | Stage IVA Uterine Sarcoma | Stage IVB Uterine Sarcoma | Stage IA Uterine Sarcoma | Stage IB Uterine Sarcoma | Stage IC Uterine SarcomaUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)CompletedBone Sarcoma | Retroperitoneal Sarcoma | Adult Soft Tissue SarcomaUnited States
-
Mohammed M MilhemGenentech, Inc.CompletedSarcoma | Soft Tissue Sarcoma | Metastatic Sarcoma | Locally Advanced Sarcoma | Unresectable SarcomaUnited States
-
National Cancer Institute (NCI)RecruitingMetastatic Alveolar Soft Part Sarcoma | Unresectable Alveolar Soft Part Sarcoma | Advanced Soft Tissue Sarcoma | Advanced Alveolar Soft Part SarcomaUnited States
-
National Cancer Institute (NCI)RecruitingMetastatic Leiomyosarcoma | Unresectable Leiomyosarcoma | Metastatic Sarcoma | Unresectable Soft Tissue Sarcoma | Metastatic Soft Tissue Sarcoma | Unresectable SarcomaUnited States
-
National Cancer Institute (NCI)CompletedRhabdomyosarcoma | Synovial Sarcoma | Ewing's Sarcoma | MPNST | High-risk SarcomaUnited States
-
Epizyme, Inc.RecruitingAdvanced Soft-tissue Sarcoma | Advanced Epithelioid SarcomaUnited States, Taiwan, Canada, United Kingdom
-
Brown UniversityActuate Therapeutics Inc.WithdrawnSoft Tissue Sarcoma | Osteosarcoma | Ewing Sarcoma of Bone | Leiomyosarcoma | High Grade Sarcoma | Liposarcoma | Rhabdomyosarcoma | Angiosarcoma | Bone Sarcoma | Synovial Sarcoma | Undifferentiated Pleomorphic Sarcoma | Myxofibrosarcoma | Spindle Cell SarcomaUnited States
-
David DickensWithdrawnSoft Tissue Sarcoma | Bone Sarcoma | Unresectable Soft Tissue Sarcoma | Metastatic Soft-tissue Sarcoma | Metastatic Bone Sarcoma | Unresectable Bone SarcomaUnited States
-
OHSU Knight Cancer InstituteNational Cancer Institute (NCI)WithdrawnStage III Adult Soft Tissue Sarcoma | Stage IV Adult Soft Tissue Sarcoma | Stage II Adult Soft Tissue Sarcoma | Stage IIA Adult Soft Tissue Sarcoma | Stage IIB Adult Soft Tissue Sarcoma | Stage IIC Adult Soft Tissue Sarcoma
Clinical Trials on OC-001
-
Shenzhen Geno-Immune Medical InstituteSuspendedOvarian CancerChina
-
University of California, Los AngelesVirtually Better, Inc.CompletedObsessive-Compulsive DisorderUnited States
-
Shenzhen Geno-Immune Medical InstituteUnknown
-
Shenzhen Geno-Immune Medical InstituteUnknown
-
OcuCure Therapeutics, Inc.CompletedProliferative Diabetic Retinopathy (PDR)Bangladesh
-
Lumbini Medical CollegeCompletedCholedocholithiasis With Cholecystitis With Obstruction | Choledocholithiasis With Acute and Chronic Cholecystitis | Cholelithiasis With Acute and Chronic Cholecystitis
-
BIXINK Therapeutics Co., Ltd.RecruitingObsessive-Compulsive Disorder | Obsessive-compulsive Disorders and SymptomsUnited States
-
Oyster Point Pharma, Inc.CompletedDry Eye DiseaseUnited States
-
National Taiwan University HospitalUnknownColorectal Cancer | Stomach DiseaseTaiwan
-
Oyster Point Pharma, Inc.CompletedLong Term Follow up Dry Eye DiseaseUnited States